Auris Medical's Tinnitus Candidate Keyzilen Fails Second Phase III Trial

06:08 EDT 14 Mar 2018 | Genetic Engineering News

Auris Medical has acknowledged the second Phase III failure in 19 months for its tinnitus candidate Keyzilen ® (AM-101), promising a future update on its plans for the company’s co-lead development program. Auris said Keyzilen failed the TACTT3 trial ( NCT02040194 ) by missing its primary efficacy endpoint of a statistically significant improvement in the Tinnitus Functional Score from baseline to day 84 in participants treated with the drug compared to those treated with placebo, either in the overall population or in the otitis media subpopulation. TACTT3, which was conducted in Europe, was designed to assess Keyzilen in acute and postacute inner ear tinnitus following traumatic cochlear injury or otitis media. The trial enrolled a combined 893 participants in the acute tinnitus stage (Stratum A) and the postacute tinnitus stage (Stratum B). The trial’s status was updated to “completed” as of January 16, the date of ...

Original Article: Auris Medical's Tinnitus Candidate Keyzilen Fails Second Phase III Trial


More From BioPortfolio on "Auris Medical's Tinnitus Candidate Keyzilen Fails Second Phase III Trial"

Quick Search


Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...